Roatán-based longevity clinic adds Klotho to its non-permanent gene therapy lineup, widening its bet on high-end healthspan medicine.
In longevity, some therapies quietly build a cult following among physicians, biohackers and investors before the wider world catches on. Klotho belongs in this category, and the specialized medical center GARM Clinic is betting that the moment of wider recognition may be getting closer.
GARM, doing business as Longevity Advanced, has announced the addition of Klotho to its advanced cell and gene therapy platform in Roatán, Honduras [1]. The move expands a growing portfolio that already includes Follistatin and VEGF, and it is clearly positioning itself as a destination for people willing to travel and pay for the next generation of longevity interventions.
Longevity is increasingly shifting from theory to offering. Not just what might work one day in a lab, but what clinics are packaging now for early adopters chasing better performance, sharper cognition and longer healthspan.
GARM’s Longevity Advanced platform is built around what the company describes as “cutting-edge, safe, non-permanent gene therapies including Follistatin, Klotho and VEGF.” That term, “non-permanent,” is worth pausing on.
Gene therapy can sound intimidating, even dystopian, to people outside the field. However, GARM is leaning into a softer, more commercially accessible framing here. Think of them more like temporary instructions delivered to the body, a short-term nudge rather than a lifelong edit.
For a general audience, they are turning a concept into something closer to a controlled biological signal – still advanced, still experimental-feeling but easier to grasp.
Why Klotho has become such a big deal
Klotho has long carried a certain mystique in longevity circles. Named after Clotho, the Greek mythological figure associated with spinning the thread of life, the protein has attracted interest because it appears linked to lifespan and healthspan. GARM describes it as “one of the most profound anti-aging factors available.”
The reason Klotho gets attention is not hard to understand. As we age, the body’s natural production of Klotho tends to decline. And when that happens, some of the systems that keep us resilient – energy production, tissue maintenance, metabolic balance – may become less efficient. If aging often feels like the body slowly losing its edge, Klotho is being positioned as one of the tools that might help preserve it.
GARM says its Longevity Advanced platform offers access to Klotho, with goals including increasing mitochondrial function, supporting organ and system health, improving mental clarity and cognition and suppressing inflammation and oxidative stress.
Klotho is being sold as a way to help the body’s “internal machinery” run more smoothly for longer. If mitochondria are the tiny power plants inside cells, Klotho is being framed as part of the maintenance crew that helps keep those power plants from sputtering too soon.
Klotho may be the new headline, but GARM is careful to present it as part of a wider strategy. The company says Follistatin remains a flagship therapy and notes that it pioneered Phase I safety studies for plasmid delivery of Follistatin in 2022. Four years later, that therapy remains central to the platform.
The appeal is straightforward: Follistatin is associated with muscle growth, bone support and lower inflammation – all areas that matter not just for aesthetics or athletic performance, but for aging well.
That is one of the more interesting shifts happening across longevity right now. The field is becoming less obsessed with abstract lifespan and more focused on function.
Can you stay stronger longer? Can you maintain mobility, cognition and energy deeper into later life? Can you delay the slow erosion that makes aging feel like decline rather than adaptation? GARM’s therapy stack is clearly built around those questions.
VEGF, another therapy already offered through the clinic, adds to that broader platform logic. It helps the body build blood vessels. More blood vessels can mean better delivery of oxygen and nutrients to tissues that need repair.
GARM notes that VEGF has been used worldwide in patients with critical limb ischemia and says the therapy has also expanded into areas such as hair restoration, exercise recovery and erectile dysfunction.
Again, GARM is not selling one miracle fix; it is building a menu around the key pressure points of aging – muscle, blood flow, tissue repair, metabolism, cognition and inflammation.
GARM Clinic, founded by US Board-Certified orthopedic surgeon Dr Glenn C Terry, has spent more than a decade building its presence in regenerative and longevity medicine. The company describes the clinic as operating in an innovative economic zone and pairing medical precision with resort luxury, explicitly targeting entrepreneurs, executives, athletes and longevity enthusiasts seeking access to advanced therapies. It is destination longevity.
That model is becoming more recognizable across the sector: advanced interventions offered outside conventional systems, wrapped in personalization, exclusivity and hospitality. For some, that raises valid concerns about access and inequality. Longevity still risks becoming a premium service first, public-health benefit later.
However, it also reveals where the market is maturing. Wealthy early adopters often fund the first wave of demand for frontier medicine. If therapies prove durable, safer and more scalable over time, what starts as elite experimentation can sometimes become a broader clinical pathway.
What this means for longevity now
GARM’s Klotho launch does not settle the science of aging. It does not prove that longevity medicine has cracked the code. And like much of the field, it sits in a space where excitement, early clinical use and commercialization are moving faster than universal consensus. Still, that is exactly why this announcement is worth watching.
Klotho’s arrival at GARM is not just about a single protein in a single clinic on a single island. It is about how longevity medicine continues to move out of the margins and into the real, investable world.
